🔎 Trials Near Me

መነሻ › ናሶፋሪንጂያል ካርሲኖማ › ጆርጂያ

በጆርጂያ ለናሶፋሪንጂያል ካርሲኖማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለናሶፋሪንጂያል ካርሲኖማ የሚደረጉ 6 ጥናቶች በጆርጂያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በጆርጂያ ውስጥ ያሉ ከተሞች

Official study text (English)

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  • Emory University Hospital Midtown, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06980038

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

  • Emory University Hospital Midtown, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT06029270

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እስከ እድሜ 21 · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06064097

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

  • Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT06662058

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ማርች 2026 · NCT06868433

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ፌብሩ 2026 · NCT06636734

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።